General Prognostics Inc.

GPx continuously monitors digital biomarkers from cardiac disease patients for disease progression. When the algorithm detects a significant change, the patient is asked to collect a blood sample and send it to our lab. If the lab results confirm that the patient is undergoing decompensation, the physician and patient are notified to act. Our business model is a subscription service charged to the hospital per patient monitored per quarter.